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ABSTRACT 
Objective: The objective of present work was to evaluate the effectiveness of propofol in nanoemulsion-based palm oil that called as NEMS™, which 
was a choice of anesthetic drug to induce and maintenance general anesthesia to reduce pain on injection activity and also to evaluate the in vivo 
characterization of propofol in NEMS™. 
Methods: Preparation of propofol nanoemulsion using NEMS™ technology has been performed for propofol 1% in NEMS™ (P1%), and propofol 2% 
in NEMS™ (P2%). Determination of free propofol concentration in the aqueous phase was conducted using HPLC and rat paw lick test was evaluated 
as in vivo test to assay the intensity of pain on injection site. The sleep recovery test was conducted to evaluate the pharmacological effect and 
erythrocyte hemolysis test also conducted to ensure the safety of propofol in NEMS™. All of the test results were compared with Diprivan®
Results: The contents of free propofol in formulation P1% and Diprivan
1% as a 
positive standard.  
®1% in aqueous-phase were 6.20±0.03 µg/ml and 15.02±0.33 µg/ml, 
respectively (*P<0.05). The rat paw lick test showed that the formulation P1% was significantly (*P<0.05) less painful when compared to 
Diprivan®1%. There were no significant differences in pharmacological effect for all of the formulations (*
Conclusion: Palm oil can be used as a carrier for propofol and it was successfully reduced the free propofol contents and the intensity of pain on 
injection site in rats.  
P>0.05). The erythrocyte haemolysis test 
shows that all formulation was still safe for our blood.  
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Propofol nanoemulsion using soya as the oil phase has been used for 
decades in clinical application. This drug is widely used in surgery 
procedure and also generally used in an intensive care unit all 
around the world. Perhaps, this is the reason why it becomes one of 
the popular anesthetic agents [1]. So far, this dosage form is reputed 
success because it has a rapid onset of action, short duration of 
action and minimum side effects [2]. 
Unfortunately, it was found so many disadvantages from this dosage 
form. Pain of injection is one of the serious problems that often happen 
to the patients [3-5]. Many researchers have tried to find the solution 
how to reduce the pain such as by using rapid injection technic [6], 
utilizing the analgesic drug before injection, such as lidocain [7], 
ephedrine [8], saline dilution [9], paracetamol [10], lornoxicam [11], etc. 
However, the best solution to treat the pain has not been discovered [4]. 
Further studies are needed to make an effective formulation. 
The clear mechanism why there is pain on site following injection is 
still not well understood. Some researchers make an assumption 
that the free propofol in the aqueous phase of propofol 
nanoemulsion is known to be related with the intensity of pain at the 
injection time [12]. The utilization of propofol nanoemulsion using a 
mixture of medium chain triglyceride (MCT)/long-chain triglyceride 
(LCT) to reduce the intensity of pain has become one of the safety 
solutions to be used [3, 13-15]. Yamakage et al. [14] stated that 
MCT/lCT propofol nanoemulsion reduces the concentration of free 
propofol until 30-35% so that it will reduce the pain.  
In this study, palm olein oil (POO) as the source of palm oil was used 
instead of soya oil as an oil phase in propofol nanoemulsion 
preparation. This oil is easily to find and commonly people use it as 
cooking oil, in margarine preparation and as an additive for food 
preparation [16, 17]. However, the application of this oil in 
pharmaceutical was still uncommon although this oil has the 
potentiality to be developed. Production of this oil every year is very 
high. This oil came originally from West Africa and it was introduced 
to Brazil and other topical countries in 15th
In the present study, the comparison in intensity of pain from P1% and 
P2% with Diprivan®1% was evaluated by determination of free 
propofol concentration in the aqueous phase by HPLC method. The rat 
paw lick test was performed to compare the intensity of pain in animals 
after injection. The sleep recovery test was conducted to compare the 
pharmacological effect of the formulations to Diprivan®. 
century. Currently, 
Malaysia and Indonesia are two countries with the highest 
production of palm oil in the world [18]. 
MATERIALS AND METHODS 
Materials 
The following materials were obtained from the sources in brackets. 
Pure Propofol and Lipoid E-80 (GmbH, Ludwigshaffen, Germany), 
Malaysian local palm oil for source of palm olein oil (POO) and MCT 
oil (Enersos, PharmaD Sdn. Bhd, Malaysia), Glycerol (Sigma Aldrich, 
Germany). Diprivan®
Methods 
 was supplied by Astra Zeneca Macclesfield, UK. 
Double distilled water was used for all preparations. Chemicals for 
high-pressure liquid chromatography (HPLC) were HPLC grade and 
all other chemicals were analytical grade. 
Preparation propofol nanoemulsion in NEMS™ 
The preparation of nanoemulsion was adopted from Prasetyo, et al. 
[19]. The nanoemulsion was prepared using the mixture of POO and 
MCT oil (1:1). High-pressure homogenizer was chosen as the method 
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to produce the nanoemulsion. POO, MCT oil, propofol (1% and 2%) 
and all ingredients that dissolved in oil were mixed in oil phase at 70 
°C. The water-soluble ingredients were mixed in the aqueous phase 
using the same temperature. Then, the mixture was homogenized by 
using homogenizer at 10,000 rpm for 6 min. The final nanoemulsion 
was prepared by using high-pressure homogenization methods at 600 
bar and 8 cycles. All of preparation processes were done aseptically in 
a clean room to ensure the sterility of nanoemulsion product.  
Determination of free propofol concentration in aqueous phase 
The determination method was adopted from Schicher et al. [20]. 
Propofol nanoemulsion (8.9 ml) in optiseal tube (Beackman coulter, 
USA) was centrifuged at 30,000 rpm and 4 °C for 5 h. The aliquot (10 
µl) was taken using syringes and injected to the HPLC system to 
determine the concentration of free propofol contents. The HPLC 
analysis was performed with Waters system. The HPLC system was 
composed of a controller (Waters 600), a degasser AF, an 
autosampler (Waters 2707), and a photodiode array detector 
(Waters 2998). The separation was achieved with a reversed phase 
C18 (25 cm×4.6 mm; 5 µm particles) column. The mobile phase 
consisted of methanol and deionised water. It was sonicated for 15 
min and then filtered through a 0.45 µm membrane filter paper. The 
wavelength use was 276 nm. Chromatography analysis was 
performed at ambient temperature (20±2 °C). 
Animals 
Male Sprague-Dawley rats weighing 300±20 g were obtained from 
Animal House of University Kebangsaan Malaysia. All rats were 
acclimatized to their environment for 1 w before the test. All rats 
were kept in the stainless steel cage and had free access to standard 
pellet and water ad libitum. The rats were exposed to 12-h periods 
of light and darkness. The temperature and humidity of the room 
were maintained at 22±2 °C and 65%, respectively. Animal protocols 
were approved by the Animal ethic Committee of Universiti 
Kebangsaan Malaysia (FF/2010/Fuad/17 March/298 March 2010-
April 2011). The rats were not provided to food 12 h before tests 
were conducted, but had free access to water. 
Rat paw lick test 
Twenty four male Sprague Dawley rats were grouped in 4 groups (6 
rats for each group). Each group had been given a different injection. 
The injections were normal saline as a negative control, P1%, P2% 
and Diprivan®
Eighteen rats were divided to 3 groups and 6 rast for each group 
(group 1 for P1%, group 2 for P2% and group C for Diprivan
 1% as the positive control, respectively. Injection 
(100 µl) was given to each rat into the footpad of their hind paws. 
Then, the number of licking and the total time of the paws being 
licked was monitored over a period of 15 min. The method was 
adapted from Lu et al. [21]. 
Sleep recovery test 
®
Erythrocyte haemolysis test 
). The 
test was conducted by giving an intravenous bolus injection of 
propofol nanoemulsion for 10 mg/kg body weight of rats on lateral 
tail vein. Each rat was observed from the beginning after injection. 
The time when the rats first moved after injection and when the rats 
become normal (full recovery) were assayed. The methods were 
adapted from Ravenelle et al. [22]. 
The test was performed as reported in the literature [23]. The rat’s 
blood was collected into a test tube containing heparin and 
centrifuged at 2000g for 5 min. Washed 3 times with 4 volume 
normal saline. 2% propofol nanoemulsion (2.5 ml) was mixed 
erythrocytes suspension (0.1 ml) and incubated at 37 °C for 1 hour 
in a water bath. Then, the sample was centrifuged at 2000g for 5 
min. The absorbance from the supernatant was determined by using 
spectrophotometer UV in wavelength 415 nm to determine % of 
haemolysis. The percentage of haemolysis was determined by using 
this equation [24]: 
 
Where: Abs test= Absorbance of samples 
Abs control= Absorbance of the negative control (normal saline) 
Abs 100= Absorbance of positive control (distilled water 
Statistical analysis 
All the data were analysed using Statistically Package for Social 
Sciences (SPSS) version 16.0. Data were expressed as means±SD 
Data were performed using analysis of variance (ANOVA) test to 
evaluate the differences between the groups. All experiments were 
done in triplicate. The differences were considered to be significant 
at level of *
RESULTS AND DISCUSSION 
P ≤ 0.05. 
Nanoemulsion are one of the dosage form that develop not only for 
oral route [25, 26], topical usage [27] but also populer for parenteral 
usage like propofol nanoemulsion. Propofol is one of the anesthetic 
drug that common usage in the hospital but the pain problem make 
this drug become not comfortable to use. Free propofol in aqueous 
phase from the palm oil nanoemulsion was separated from oil phase 
by using ultracentrifugation methods and measured using HPLC. The 
chromatograph of propofol in NEMS™ from HPLC result shown in fig. 1 
and the results of free propofol content showed in fig. 2. The free 
propofol concentration of P1% and P2% were 6.20±0.03 µg/ml, 
10.55±0.23 µg/ml, respectively. The results were smaller than in 
Diprivan® 1% (15.02±0.33 µg/ml). Statistical test showed that there 
was a significant difference between P1% compared with Diprivan® 
1% (*P<0.05) whereas P2% showed no significant differences 
although it showed the smaller free propofol concentration. The 
results showed that propofol in NEMS™ reduced the intensity of pain 




Fig. 1: Chromatograph of propofol in NEMS™ 
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Fig. 2: Free propofol content in P1% and P2% compared with Diprivan®
 
The clear mechanism how propofol induced pain on injection site is still 
not well understood. One of the possibility is because propofol is one of 
phenol that can irritate the skin, mucous membrane, and venous intima 
[28]. The other opinion stated that the activation of the kallikrein-kinin 
system will induce in pain [29]. Many studies showed that, the intensity 
of pain related to increase the free propofol concentration in aqueous 
phase. This is one of the reason why MCT/lCT formulation become one 
of the solution to decrease this problem [30, 31]. 
 1% (mean±SD; n=6) 
Propofol nanoemulsion in NEMS™ is one of the MCT/lCT formulation 
for propofol that using palm oil as a basic oil to develop the 
formulation. From this formulation, hopefully it will reduce the free 
propofol concentration and it can be used as alternative for propofol 
carrier in nanoemulsion preparation. Determination of free propofol 
concentration were performed to assay the free propofol 
concentration. In this formulation, the concentration of free propofol 
in NEMS™ is smaller than in Diprivan® from the rat paw lick test, the 
intensity of pain from propofol in NEMS™ is lower than Diprivan®
The rat paw lick test was performed to observe if there were a relation 
between content of free propofol concentration and pain in the animal 
test. This test was done as in vivo test to measure the intensity of pain 
of propofol nanoemulsion at injection site. The principle of this test 
was if the intensity of the nanoemulsion increase, so the number of 
rats licking their paw and the number of time licking also increased 
[32-34]. As can be seen from table 1, the licking happened in all of the 
formulations. The results showed that P1% and P2% had less licking 
compared to Diprivan
. 
® 1%. Statistical test showed that there was a 
significant difference between P1% and Diprivan® 1% (*P<0.05). 
whereas P2% showed no significant differences. This results showed 
an appropriateness with free propofol concentration in aqueus phase 
in case where free propofol concentration of propofol in NEMS™ 
showed smaller that in Diprivan® therefore it can reduce the pain. In 
P2%, the free propofol concentration were still quite high because not 




Table 1: Results of rat paw-lick test 
Formulation The number of licking (time) The number of time of licking (min) 
Normal saline 2.5±0.7 19.5±6.4 
P1% 8.3±1.2* 39.5±6.7* 
P2% 9.8±2.0 46.6±12.1 
Diprivan® 11.2±1.9  1% 59.5±7.3 




Fig. 3: Profile of sleep test recovery of propofol in NEMS™ compared with diprivan® 1% (mean±SD; n=6) 
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It was observed from fig. 3., that there were no significant 
differences (p>0.05) between P1%, P2% and Diprivan® 1% as 
standard. All rats started to sleep not more than 1 min after 
injection. From this test, the effect of propofol in NEMS™ almost 
similar with Diprivan® 1% in all parameters test. The rats started to 
open their eyes after 8 min, try to wake up after 9 min and back in 
normal condition after 15 min. NEMS™ showed a very good result in 
pharmacological test. This carrier had similar effect with Diprivan®
Haemolysis test 
. 
It meant that the drug had a good release profile after being injected 
to the rats. There were no significant differences (p>0.05) between 
all of the formulations.  
The purpose of this test was to ensure that this formula would give 
damage or not to the blood [35]. The result showed that distilled 
water caused 100% hemolysis in blood. Whereas P1%, P2% and 
Diprivan®
 
 1% were cause a little bit hemolysis in blood, but it was 
still fulfilled the safety requirement (fig. 4). Parenteral 
administration of the drug still safety to use if the % haemolysis of 
the formulation below than 20% [36]. The reason of this phenomena 
happen is due to the composition of the emulsion like a phospholipid 
in emulsion would cause interaction with red blood cell [37]. 
 
Fig. 4. The amount of red blood cell remaining after hemolysis test (mean±SD, n=6) 
 
CONCLUSION 
In summary, palm oil in NEMS™ has proven its potential to produce 
a propofol nanoemulsion and from the results indicated that palm 
oil in NEMS™ is promising carrier system for propofol and 
successfully reduced the free propofol contents and the intensity of 
pain on injection site in rats. 
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